成都静脉曲张检查要多少费用成都前列腺肥大哪家比较好,成都看睾丸精索静脉曲张哪家医院好,成都哪个医院可以医糖足,成都雷诺氏症哪里治疗好,成都治疗血管畸形哪种方法效果好,成都怎么治疗血管畸形好办法,成都哪里看雷诺氏症

BEIJING, Sept. 9 (Xinhua) -- Lenovo Group, China's largest PC maker, said it aims to become the world's second-largest PC provider by the end of this year, China Daily reported Friday.The PC maker will take aggressive action to expand in the international PC market left by its competitors because of strategy adjustment, the English newspaper quoted Liu Chuanzhi, the board chairman of Lenovo, as saying.A few weeks ago, the world's biggest PC maker Hewlett-Packard Corp. said it will spin off its PC sector. Apple Inc's former CEO Steve Jobs resigned."The Chinese market is the starting point for Lenovo, but it won't be the only place Lenovo should put emphasis on. We will set up a more active strategy for expanding in overseas markets," Liu said.The PC maker has long been focusing on the global market. It purchased the PC division of the IBM Corp. a few years ago. In January, it announced a 175-million-U.S.-dollar joint venture with Japan's NEC Corp. In July, Lenovo completed its acquisition of Medion AG, a German multimedia and consumer electronics maker.

SAN FRANCISCO, July 7 (Xinhua) -- Apple announced Thursday that over 15 billion applications have been downloaded from its App Store by more than 200 million Apple mobile devices users worldwide."Thank you to all of our amazing developers who have filled it with over 425,000 of the coolest apps and to our over 200 million iOS users for surpassing 15 billion downloads," said Phillip Schiller, Apple's senior vice president of worldwide product marketing, in a statement.Launched on July 10, 2008, Apple's digital application distribution platform has been growing at a fast speed. It took nine months to hit one billion downloads and five billion in June 2010. In January, Apple gave a 10,000-U.S. dollar App Store gift card to a user who downloaded the 10 billionth application.In Thursday's statement, the Cupertino, California-based company said it had paid developers 2.5 billion dollars to date.Apple's mobile market place is far ahead of Google's Android Market. At its annual I/O conference in May, Google said there had been 4.5 billion app installs so far. But Google said the growth of its mobile operating system and applications is accelerating with its store hitting another billion downloads every 60 days.Currently, Apple is in a legal battle against Amazon over the use of "Appstore," which the online retailer launched in March to sell mobile applications to Google's Android platform users.On Wednesday, a federal judge denied Apple's request to immediately stop Amazon from using the term "Appstore."Meanwhile, Amazon, Microsoft, HTC, Nokia and Sony Ericsson have filed complaints against Apple in Europe, seeking to get Apple's trademarks for "App Store" and "Appstore" invalidated.

WASHINGTON, Aug. 16 (Xinhua) -- The White House announced Tuesday that the U.S. Departments of Agriculture, Energy and Navy will invest up to 510 million U.S. dollars in partnership with the private sector to facilitate the country's biofuel industry development."Biofuels are an important part of reducing America's dependence on foreign oil and creating jobs here at home," U.S. President Barack Obama said in a White House statement.The initiative is a response to a directive from Obama issued in March as part of the Blueprint for A Secure Energy Future, the administration's framework for reducing dependence on foreign oil."But supporting biofuels cannot be the role of government alone. That's why we're partnering with the private sector to speed development of next-generation biofuels that will help us continue to take steps towards energy independence and strengthen communities across our country," Obama added.The joint plan calls for the three departments to invest up to 510 million dollars in the next three years, which will require substantial cost share from private industry, in a bid to reduce U. S. reliance on foreign oil and create jobs at home."By building a national biofuels industry, we are creating construction jobs, refinery jobs and economic opportunity in rural communities throughout the country," said U.S. Agriculture Secretary Tom Vilsack.White House figures revealed that the world's largest economy spends more than 300 billion dollars on imported crude oil every year.With a slackening economic recovery and the government's approval rate at a record low level, the Obama administration is rolling out a string of measures in recent days to accelerate economic growth and job creation.

BEIJING, Sept. 9 (Xinhua) -- Lenovo Group, China's largest PC maker, said it aims to become the world's second-largest PC provider by the end of this year, China Daily reported Friday.The PC maker will take aggressive action to expand in the international PC market left by its competitors because of strategy adjustment, the English newspaper quoted Liu Chuanzhi, the board chairman of Lenovo, as saying.A few weeks ago, the world's biggest PC maker Hewlett-Packard Corp. said it will spin off its PC sector. Apple Inc's former CEO Steve Jobs resigned."The Chinese market is the starting point for Lenovo, but it won't be the only place Lenovo should put emphasis on. We will set up a more active strategy for expanding in overseas markets," Liu said.The PC maker has long been focusing on the global market. It purchased the PC division of the IBM Corp. a few years ago. In January, it announced a 175-million-U.S.-dollar joint venture with Japan's NEC Corp. In July, Lenovo completed its acquisition of Medion AG, a German multimedia and consumer electronics maker.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.